Forksiga of the tab. of p/o of 10 mg No. 30

Tablets of Forksiga are shown to adults for treatment of insufficiently controlled diabetes 2 types as addition to a diet and physical activities; as monotherapy when use of metformin is considered impossible because of intolerance of drug; in combination with other medicines for treatment of type 2 diabetes.

Structure

Active ingredient: dapagliflozin;

1 tablet, coated, contains 6.15 mg 12.30 mg to a monohydrate pro-pan-diol dapagliflozin in terms of dapagliflozin 5 mg or 10 mg;

Excipients: cellulose microcrystalline, lactose, krospovidon, silicon dioxide, magnesium stearate, opadray AI yellow.

Contraindication

Hypersensitivity to active ingredient or to any of excipients.

Route of administration

Forksiga Medicine needs to be accepted inside once a day at any time, irrespective of meal. It is necessary to swallow of tablets entirely.

Pregnant

it is not recommended by

Feature of use

Drivers

With care.

Dapagliflozin did not show to

any signs of toxicity at healthy participants of a research at oral administration of single doses to 500 mg (50 times higher than the maximum recommended dose for the person). In these participants of a research it was possible to find glucose in urine during the dose-dependent span (not less than 5 days for a dose of 500 mg) without cases of dehydration, arterial hypotension of an electrolytic imbalance and also without clinically significant action on QTc interval. Frequency of development of a hypoglycemia was similar frequencies in group of use of placebo.

should begin with

in case of overdose the corresponding supporting treatment, is defined by a clinical condition of the patient. A conclusion of a dapagliflozin by means of a hemodialysis was not studied.

Side effects

from a metabolism and food: hypoglycemia.

Interaction

Use of a dapagliflozin can increase diuretic effect of thiazide and loopback diuretics and also can increase risk of developing dehydration and arterial hypotension.

Insulin and means strengthening insulin secretion such as sulphonylurea drugs, cause development of a hypoglycemia. Thus, for reduction of risk of development of a hypoglycemia at use in a combination with dapaglifloziny there can be reasonable a use of lower doses of insulin or the means strengthening insulin secretion.

to Store

out of children's reach at a temperature up to 25 °C.

Expiration date - 3 years.